This article has Open Peer Review reports available.
Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
© Dimberg et al.; licensee BioMed Central Ltd. 2012
Received: 12 March 2012
Accepted: 12 July 2012
Published: 28 July 2012
Multiple myeloma (MM) is at present an incurable malignancy, characterized by apoptosis-resistant tumor cells. Interferon (IFN) treatment sensitizes MM cells to Fas-induced apoptosis and is associated with an increased activation of Signal transducer and activator of transcription (Stat)1. The role of Stat1 in MM has not been elucidated, but Stat1 has in several studies been ascribed a pro-apoptotic role. Conversely, IL-6 induction of Stat3 is known to confer resistance to apoptosis in MM.
To delineate the role of Stat1 in IFN mediated sensitization to apoptosis, sub-lines of the U-266-1970 MM cell line with a stable expression of the active mutant Stat1C were utilized. The influence of Stat1C constitutive transcriptional activation on endogenous Stat3 expression and activation, and the expression of apoptosis-related genes were analyzed. To determine whether Stat1 alone would be an important determinant in sensitizing MM cells to apoptosis, the U-266-1970-Stat1C cell line and control cells were exposed to high throughput compound screening (HTS).
To explore the role of Stat1 in IFN mediated apoptosis sensitization of MM, we established sublines of the MM cell line U-266-1970 constitutively expressing the active mutant Stat1C. We found that constitutive nuclear localization and transcriptional activity of Stat1 was associated with an attenuation of IL-6-induced Stat3 activation and up-regulation of mRNA for the pro-apoptotic Bcl-2 protein family genes Harakiri, the short form of Mcl-1 and Noxa. However, Stat1 activation alone was not sufficient to sensitize cells to Fas-induced apoptosis. In a screening of > 3000 compounds including bortezomib, dexamethasone, etoposide, suberoylanilide hydroxamic acid (SAHA), geldanamycin (17-AAG), doxorubicin and thalidomide, we found that the drug response and IC50 in cells constitutively expressing active Stat1 was mainly unaltered.
We conclude that Stat1 alters IL-6 induced Stat3 activity and the expression of pro-apoptotic genes. However, this shift alone is not sufficient to alter apoptosis sensitivity in MM cells, suggesting that Stat1 independent pathways are operative in IFN mediated apoptosis sensitization.
Multiple myeloma (MM) is a malignancy characterized by an accumulation of plasma cells/ plasma blasts in the bone marrow. Common complications of MM include anemia, renal dysfunction, and bone destruction. Conventional drugs such as alkylating agents and corticosteroids, autologous and allogeneic bone marrow transplantation, bisphophanates, and novel drugs such as thalidomide, bortezomib, and lenalidomide can improve the quality of life and extend patient survival . However, resistance to therapy often develops, making MM uniformly fatal.
A biological or mechanistic approach to combat drug resistance is to delineate the specific factors that are important in the regulation of growth, apoptosis and survival in MM. Thereby, putative critical drug targets for increased drug efficacy and circumvention of apoptosis resistance can be defined . Ideally, therapy could be individualized based on the expression profile of the malignant plasma cells of the individual patient.
The aim of this study was to evaluate the importance of signal transducer and activator of transcription (Stat) 1 in influencing apoptosis and drug resistance in MM. Stat1 belongs to a family of transcription factors that are associated with regulation of growth and survival in hematopoietic cells. Upon cytokine stimulation, these proteins become phosphorylated by kinases, such as janus activated kinases (JAKs), associate with the cytoplasmic part of the cytokine receptor, form homo- or heterodimers and, finally, translocate to the nucleus where they bind to specific DNA elements and directly regulate transcription [3, 4].
The Stat proteins Stat1 and Stat3 are constitutively activated in several types of tumors  including MM [6, 7]. Stat3 is predominantly activated by the MM growth and survival factor IL-6. Stat1 is mainly activated by interferons, but can also to some extent be activated by IL-6 . Stat3 has been defined as an oncogene in light of its ability to mediate cellular transformation and block apoptosis . Some downstream targets of Stat3 that have been suggested to mediate these effects are anti-apoptotic Bcl-2-proteins and cell cycle regulators i.e. Bcl-XL, Mcl-1, c-Myc, and Cyclins D1/D2 . In MM, the survival promoting effect of Stat3 has been ascribed to an up-regulated expression of the anti-apoptotic Bcl-2 family member Bcl-XL . In contrast to Stat3, Stat1 has been proposed to promote apoptosis rather than survival [11–15]. It has been suggested that the relative abundance of the Stat1 and Stat3 proteins may influence the activity of each other. Supporting this hypothesis, Stat3 expression and activation is enhanced in Stat1 null cells  and, conversely, Stat1 expression and activation is enhanced in Stat3 null cells . In ischemia / reperfusion mediated apoptosis, Stat1 was shown to promote apoptosis by down-regulating the Bcl-2 and Bcl-XL genes, whereas Stat3 counteracted this effect by up-regulating these genes . Several inhibitors of Stat3 signaling have been developed (reviewed in ) for anti-cancer therapy, including a hairpin decoy oligonucleotide. This inhibitor was designed to block Stat3 but not Stat1 function, thereby presumably avoiding the tumor antagonist effects of Stat1 .
We have previously reported that MM cells that are highly resistant to Fas-induced apoptosis can be re-sensitized by pretreatment with IFN-γ . One underlying cause for this effect was IFN-γ-induced up-regulation of the Fas receptor (CD95). Interestingly, we found that in addition to inducing and activating Stat1, IFN-γ also deactivated Stat3 . In light of this observation, we hypothesized that one mechanism of IFN-γ mediated sensitization to apoptosis was deactivation of anti-apoptotic Stat3, possibly as a consequence of increased transcriptional activation and expression of Stat1.
To delineate the role of Stat1 in IFN mediated sensitization to apoptosis induced by Fas and therapeutically relevant drugs, we established sub-lines of the IL-6 dependent MM cell line U-266-1970 with a stable over-expression of wild type Stat1 as well as its active mutant Stat1C . The Stat1C was utilized to obtain Stat1 homodimers and transcriptional activation also in the absence of IFN-γ induced tyrosine phosphorylation. To determine whether Stat1 alone would be an important determinant in sensitizing MM cells to apoptosis, the U-266-1970-Stat1C cell line and control cells were exposed to high throughput compound screening (HTS). In addition, we explored the influence of Stat1C constitutive transcriptional activation on endogenous Stat3 expression and activation, and the expression of apoptosis-related genes.
We report here that constitutive transcriptional activation of Stat1 in the U-266-1970 MM cell was indeed associated with an attenuation of Stat3 activation and a differential expression of several genes involved in apoptosis. However, Fas-induced apoptosis was not augmented in the U-266-1970-Stat1C cells, suggesting that increased activation of Stat1 transcription alone does not confer increased sensitization to Fas-induced apoptosis in MM. In a high through-put screening (HTS) of more than 3000 drugs, including bortezomib, dexamethasone, etoposide, suberoylanilide hydroxamic acid (SAHA), geldanamycin (17-AAG), doxorubicin and thalidomide, used in conventional and experimental MM therapy, as well as compounds from two annotated drug libraries, we found that IC50 was not reduced in U-266-1970-Stat1C. In fact, for two related agents, gitoxin and gitoxigenin, Stat1C conferred resistance rather than increased sensitivity. We conclude that shifting the balance from Stat3 to activated Stat1 in MM has an impact on transcriptional activation of genes i.e. Mcl-1, Noxa and Harakiri, but that this shift alone is not sufficient to alter sensitivity to IFN mediated apoptosis sensitivity or general drug response in MM cells.
Cell culture conditions
The IL-6 dependent MM cell line U-266-1970  was maintained at 37°C in 5% CO2 in RPMI 1640 medium (Sigma Biosciences, St Louis, MO) supplemented with 10% heat inactivated fetal bovine serum (FBS; GIBCO, Grand Island, NY), 2 mM glutamine (Sigma), antibiotics (penicillin 100 U/mL and streptomycin 50 μg/mL) (Sigma), and 20 U/mL IL-6 (R&D Systems Europe Ltd, Abington, UK). For the stably transfected cells, the medium was also supplemented with G418 (Gibco). The cells were stimulated with IFN-γ, (1000 U/mL, Bender MedSystems GnbH, Vienna, Austria) as indicated. Unless stated otherwise, IL-6 was always present in the experiments. The U3A cell line, a Stat1-deficient mutant of the human fibroblast cell line 2ftgh cell line , was a kind gift from Dr. G.R. Stark. This cell line was maintained in Dulbeccos Modified Eagle´s Medium supplemented with 10% heat inactivated fetal bovine serum (FBS; GIBCO, Grand Island, NY), 2 mM glutamine (Sigma), antibiotics (penicillin 100 U/mL and streptomycin 50 μg/mL) (Sigma). All experiments were performed on exponentially growing cells.
Plasmids for transient and stable Stat1transfections
The wtStat1pcIneo plasmid has been described previously . The empty pcIneo vector (Promega) was used as a negative control. The FLAG-tagged STAT1C construct, consisting of a mutated form of Stat1 with Ala-656 and Asn-658 substituted for cysteine, a FLAG-tag, and a gene for neomycin resistance, was a kind gift from Dr. Sironi and Dr. Ouchi . The pcDNA3.1.EGFP vector expressing green fluorescent protein was used as a marker for transient transfection (Biosciences).
To obtain cells with a stable expression of wtStat1 and Stat1C in U-266-1970 cells, the cells were nucleofected using the Amaxa Nucleofector™ apparatus (Amaxa, Cologne, Germany) according to the instructions of the manufacturer. Briefly, 2 x 106 U-266-1970 cells were grown in cell medium without antibiotics for 24 hours and were then washed once in cold phosphate-buffered saline, and resuspended in 100 μl of electroporation buffer R with 4 μg of wtStat1pcIneo, empty pcIneo vector, or Stat1C vector as indicated. The cell suspension was the transferred to a 2.0 mm electroporation cuvette, and nucleofected with an Amaxa Nucleofector™ apparatus using nucleofection program U-05. 24 hours post-transfection IL-6 (20 U/ml) and G418 (1000 μg/ml) was added to the medium to select for stably transfected cells. After 6–10 weeks G418-resistant cells were maintained in cell medium with IL-6 (20 u/ml) and G418 (500 μg/ml).
For transient transfections of adherent U3A cells and 2ftgh, the calcium phosphate transfection method was used. Briefly, 6 x 106 cells were seeded in each 10 cm plate the day before transfection. Chloroquine disphosphate was added 30 minutes before transfection to the cell culture plates. DNA (10 μg) was mixed with 0.25 M CaCl2. The mixture was then added to an equal volume of 2x HEPES-buffered saline, incubated for 20 minutes and finally added to the cells. The medium was changed and IFN-γ was added 6 hour post-transfection. The cells were harvested after 24 hours of IFN-γ stimulation.
For identification of stably transfected cells expressing pcIneo and wtStat1 pcIneo, PCR was performed with forward primer 5’-AAG GCT AGA GTA CTT AAT ACG-3’ and reverse primer: 5’-ATT AAC CCT CAC TAA AGG GA-3’ (program:: 95° 7 min, (95° 25 s, 55° 25 s, 72° 30 s)x40, 72° 2 min). The reactions were performed using the Platinum Taq polymerase (Invitrogen) according to the manufacturer’s protocol.
U-266-1970 cells were incubated with 20 U/mL IL-6 alone or in combination with 1000 U/mL IFN-γ for the indicated time periods followed by harvest. For whole cell protein extracts, cells were washed once in PBS and lysed in 1% NP40, 0.1 M Tris–HCl, 0.15 M NaCl, 5 mM EDTA with protease inhibitors (1 mM ZnCl2, 50 mM Na2MoO4, 10 mM NaF, 0.1 mM NaVO3, 1 mM PMSF, 1 mM DTT, 1 x complete, EDTA-free (Roche, Mannheim, Germany) for 20 minutes at 4°C and centrifuged for 10 minutes at 4°C at 10000 X g to remove cellular debris. The supernatant was collected and the protein concentration was measured using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA). After heating the samples at 70°C for 10 minutes the protein extracts were fractionated on NuPAGE Bis-Tris pre-cast gels (4-12%, 10%, 12%) using the Novex electrophoresis and blotting system (NOVEX, San Diego, CA). The membrane (Hybond-C extra, Amersham, United Kingdom) was blocked in 5% non-fat milk in TTBS (20 mM Tris–HCl (pH 7,5), 500 mM NaCl, and 5% Tween 20) at room temperature for 1 h, and then incubated at 4°C overnight with primary antibodies diluted in TTBS + 5% non-fat milk. The membrane was then washed 5x5 minutes in 1xTTBS, and incubated with secondary horseradish peroxidase (HRP)-linked antibodies (Amersham or, for detection of Stats and actin, DAKO, Glostrup, Denmark) diluted in TTBS + 5% non-fat milk for 1 hour at room temperature. After washing 5x5 minutes in 1xTTBS, protein detection by enhanced chemi-luminescence (ECL plus; Amersham, Bucks, U.K) was performed according to the manufacturer's protocol. Primary antibodies used where α-Bcl-xL (H-62), α-Bcl-2 (C-21), α-actin (I-19), α-Stat1 (C-111), α-Stat3 (C-20), α-Mcl-1 (S-19), α-IRF-1 (C-20), α-Noxa (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Fas (UB2, Immunotech, Marseilles, France), anti-Histon H3 (ab1791) (abcam), anti-α-tubulin (A11126) (Invitrogen), rabbit polyclonal α-pStat1, rabbit polyclonal α-pStat3 (New England Biolabs, Beverly, MA, USA), α-FLIP (804-127-C100) (Alexis corporation, Läufelfingen, Switzerland), and α-FLAG (F-1804) (Sigma).
Nuclear protein lysates
U-266-1970-Stat1C, and U-266-1970-pcIneo cells were incubated with IL-6 (20 U/mL) for 24 hours and were then stimulated with IL-6 alone or in combination with 1000 U/mL IFN-γ for the indicated time points. Nuclear and cytoplasmic protein lysates were prepared essentially as described by Andrews and Faller .
Luciferase reporter assay
By using the Amaxa system as described, U-266-1970-pcIneo and U-266-1970-Stat1C cells were transiently transfected with 3 μg of the GBP-luc reporter vector (a kind gift from Dr. B. Lüscher, Hannover). The GBP-luc vector contains a luciferase reporter gene driven by a fragment of the human guanylate binding protein promoter containing Stat1-inducible ISRE and GAS elements . To normalize the luciferase values due to differences in transfection efficiency, the cells were co-transfected with 1 μg of the vector hubactp/lacZ vector. This vector, which contains 4 kb of the human β-actin promoter linked to a lacZ reporter gene, was kindly provided by Dr. U. Lendahl . Luciferase activity was measured in a luminometer (Lumat LB9501EG&G, Berthold, MA) using Luciferase Assay Reagent (Promega) according to manufacturer’s protocol. B-galactosidase activity was measured in the same luminometerusing Galacton and Emerald reagents (TROPIX; Bedford, USA) according to manufacturer’s protocol.
Multiplex Ligation-Dependent Probe Amplification Assay (MLPA)
MLPA is a mRNA quantification assay based on probes, each of which consists of two unique oligonucleotides of specific lengths, one unlabeled and one fluorescently labeled, that anneal to adjacent sites on a specific target sequence. The annealed probes are ligated, allowing amplification of target sequences with specific lengths that can be quantified by capillary sequence analysis. All the probes used in the apoptosis gene probe set and detailed protocols have been described elsewhere [30, 31]. U-266-1970-pcIneo and U-266-1970-Stat1C were incubated with 20 U/mL IL-6 (R&D Systems Europe Ltd, Abington, UK) alone or in combination with 1000 U/mL IFN-γ. The cells were harvested after 6 h and total RNA was prepared by Trizol extraction (Invitrogen) according to the manufacturer’s recommendation. Any contaminating DNA was removed using DNA-free™(Ambion). The MLPA was performed using the SALSA P011 Apoptosis mRNA MLPA kit (MRC-Holland , Amsterdam, The Netherlands) according to manufacturer’s recommendations. Briefly, 100 ng of RNA was first reverse transcribed using MMLV reverse transcriptase (Promega) together with the SALSA RT buffer and the SALSA RT primer mix. The resulting cDNA was hybridized to the SALSA probemix. Hybridized oligos were subjected to a ligation reaction, and ligation products were amplified by PCR using one labeled and one FAM-labeled primer. PCR products were analyzed on the ABI3700 capillary sequencer (Applied Biosystems) and peak areas representing gene expression was calculated using GeneScan software (ver3.7) for each gene. Data was normalized using the control gene ß-2 microglobulin, then all peak areas were summed to 100% and the relative peak area for each gene was calculated from this.
Resazurin is the active compound of the commercially available compound Alamar Blue . The resazurin assay can be used to quantify cell proliferation and cytotoxicity since the substance becomes increasingly fluorescent in the presence of metabolically active cells . U-266-1970-pcIneo and U-266-1970-Stat1C were incubated with 20 U/mL IL-6 (R&D Systems Europe Ltd, Abington, UK) alone or in combination with 1000 U/mL IFN-γ in round bottomed 96-well plates. After the indicated time points, 10% Alamar Blue (resazurin) (Serotec Limited, Oxford, UK) was added to the wells, followed by incubation for 3 h at 37°C in a humidified 5% CO2 in-air atmosphere. The resazurin assay was also used to confirm the response to drugs identified in the high throughput FMCA screening. Analysis of fluorescence was performed by using a Wallac Victor Multilabel Counter (Wallac, Turku, Finland), where the resazurin was excited at 530 nm and the emitted light was measured at 590 nm. Mean was calculated from triplicate wells and subtracted from mean of blank wells resulting in ΔFluorescence. The relative number of viable cells was expressed as percentage of untreated cells and calculated as 100 x ΔFluorescence (treated cells)/ΔFluorescence (untreated cells).
Flow cytometric analysis of apoptosis
U-266-1970 cells were incubated with 20 U/mL IL-6 alone or in combination with 1000 U/ml IFN-γ, and/or agonistic Fas-antibody CH-11 (100 ng/mL:, Immunotech, Marseilles, France) and/or isotype specific control IgM (X-0942, 100 ng/mL, DAKO A/S, Glostrup, Denmark). The percentage of Annexin V-positive/PI-negative apoptotic cells was measured on a FACScan flow cytometer and analyzed with CellQuest software (Becton Dickinson, San José, CA, USA), using the Annexin V-FITC kit (Calbiochem) or, when analyzing EGFP-transfected cells, with the Annexin V, Alexa Fluor 647 kit (Molecular Probes, Oregon, USA) according to the manufacturer’s protocol.
Fluorometric Microculture Cytotoxicity Assay (FMCA)
The FMCA is an automated assay that measures fluorescence generated from hydrolysis of fluorescein diacetate to fluorescein by cells with intact plasma membranes . In this assay, the sensitivity to drugs is determined by calculating a survival index (SI%), defined as the 100 x ΔFluorescence (treated cells)/ΔFluorescence (untreated cells), which is proportional to the number of living cells. Cell cultures were seeded in drug-prepared plates up in 384 well plates at a density of 10 000 cells/ well and treated as described elsewhere . The drugs used in the assay were etoposide, SAHA, dexamethasone, doxorubicin, As203, bortezomib, irinotecan, amsacrine, parthenolide, fludarabine, IMD 0354, 17-AAG/geldanamycin, TBB, docetaxel, oncovin, and resveratrol. For each drug, five different concentrations were used. For each drug, IC50-values (inhibitory concentration 50%) were calculated by using non-linear regression and a standard sigmoidal dose–response model in the GraphPadPrism program (GraphPad Software, Inc. San Diego, CA, USA). The FMCA assay was also used to screen the Library of pharmacologically active compounds (LOPAC1280) (Sigma-Aldrich, St. Louis, Mo.) consisting of 1266 drugs from 56 pharmacological classes and the Spectrum Collection (MicroSource Discovery Inc., Groton, Conn.) consisting of 2000 drug components, natural products and bioactive components. All the LOPAC drugs were screened at a concentration of 10 μM. An Accord HTS database (Accelrys Inc, San Diego, CA, USA) and Small Laboratory Information and Management System (SLIMS: Kelley, Lunn, Stockwell 2004) were used for screening data management and analysis. Raw data files were loaded into the SLIMS software which calculates percent inhibition according to the formula: Percent inhibition = 100 x (test well-blank/control-blank)-1.
Establishment of U-266-1970 cells sublines with a stable expression of Stat1C
To evaluate Stat protein expression and activation in the different sublines (designated U-266-1970-wtStat1pcIneo (data not shown), U-266-1970-Stat1C, and U-266-1970-pcIneo), we stimulated the cells with IFN-γ and harvested them at the indicated time points. Stat1C-transfected cells displayed a pronounced increase in Stat1 expression and a marked enhancement of IFN-γ induced tyrosine phosphorylation (Figure 1C). The U-266-1970-Stat1C subline was chosen for further analysis outlining the role of Stat1 on gene expression and apoptosis sensitization.
Nuclear translocation of Stat1C and increased transcriptional activity in U-266-1970-Stat1C cells
To confirm that the nuclear presence of Stat1C in the U-266-1970-Stat1C sub-line was reflected by an increased Stat1-induced transcriptional activation, we analyzed the protein expression of the well-characterized IFN-inducible gene interferon regulatory factor 1 (IRF-1) in the sublines. Figure 2B shows that both the basal expression and the IFN-γ induced expression of IRF-1 were significantly increased in the Stat1C transfected subline (see also Additional file 1: Figure S1). Consistent with increased Stat1 activity we also observed a statistically significant (>2-fold) higher transcription from GBP-luc, a luciferase reporter containing Stat1-inducible ISRE and GAS elements, in Stat1C expressing U-266-1970 cells as compared to untreated control cells (Figure 2C). As expected, the increase in transcriptional activity was further enhanced by the treatment of IFN-γ in both U-266-1970-Stat1C and U-266-1970-pcIneo cells.
Regulation of apoptosis-related genes in U-266-1970-Stat1C cells
Differentially expressed genes in U-266-1970-Stat1C cells versus U-266-1970-pcIneo cells, untreated or IFN-γ-treated
Fold expression in Stat1C vs pcIneo
Fold expression in Stat1C/IFN-γ vs pcIneo/IFN-γ
The MLPA analysis did not reveal a regulation of the Bcl-2 and Bcl-XL genes at the transcriptional level. However, given the previously established link between these proteins, Stat activation and survival [6, 18], we were interested in whether the level of Bcl-2 and Bcl-XL protein expression would differ between the U-266-Stat1C cell line and the vector transfected subline. In addition to these genes, the protein expression of Mcl-1 was assayed, the short form of Mcl-1 being the gene most consistently up-regulated at the mRNA level in the Stat1C subline. As shown in Figure 4B, the Bcl-2, Bcl-XL and Mcl-1 were, however, not significantly different at the protein expression level in the U-266-1970-Stat1C sub-line. IFN-γ stimulation did not have any major effect on the protein expression of any of the genes examined (see also Additional file 1: Figure S2).
Stat1 activation attenuates IL-6 induced Stat3 activity in U-266-1970 cells
The effect of Stat1 on the sensitivity to Fas-induced apoptosis in MM cells
The effect of Stat1 on drug sensitivity in MM cells
In an unbiased high throughput screening, we exposed the sublines to the 1266 drugs of the LOPAC library and to the 2000 pharmacologically active substances of the Spectrum Collection library. Only 18 of the drugs of the LOPAC induced a survival index lower than 50% at a concentration of 10 μM in any of the sub lines (data not shown), confirming the fact that myeloma cells are highly resistant to apoptosis. We arbitrarily considered 20% of difference in survival index between empty-vector transfected and Stat1-transfected sub-lines to be a potentially relevant difference. Several drugs induced a differential response in the cell lines using this criterium, but when repeating the experiments on a smaller scale using resazurin assay, only 2 drugs (gitoxin and gitoxigenin) could be confirmed as yielding statistically significant changes in apoptosis sensitivity in the two cell lines, the Stat1 expressing cells being more resistant than control cells (Additional file 1: Figure S5).
An important challenge in MM research lies in pinpointing the critical factors that regulate growth and survival so that potential therapeutic targets can be defined. Stat1 is constitutively activated in many MM patients , and has been described as a pro-apoptotic protein in a number of studies [12–14]. In contrast, the family member Stat3, has been identified as a pro-survival protein activated downstream the MM growth- and survival factor IL-6 [6, 7, 36, 37] and as a promising drug target [19, 20]. Both proteins can be regulated by IL-6 and by interferons, they can bind to the same DNA motifs, they are highly homologous to each other, and they can form heterodimers of Stat1/Stat3 that may have other specificities in gene regulation as compared to either homodimer alone . It has also been suggested that Stat1 and Stat3 can oppose the effects of each other [16, 39–41], for instance by exerting opposing effects on the promoters of pro- or antiapoptotic genes .
We have previously found that IFN-γ sensitizes MM cells for apoptosis induced by the death receptor Fas  by a mechanism involving up-regulation of the Fas receptor . Intriguingly, we found that IFN-γ stimulation induces not only Stat1 activation but also Stat3 deactivation . In the present study we show that Stat3 protein was decreased and phosphorylation of Stat3 was attenuated in an IL-6 dependent MM cell line, the U-266-1970 , expressing a constitutively active mutant of Stat1, the Stat1C. This observation is in line with other studies that have shown enhanced Stat3 expression and activation in Stat1 null cells  and, conversely, enhanced Stat1 expression and activation in Stat-3 null cells . It is also consistent with the finding that IFN-α induced apoptosis of MM cells is associated with inhibition of Stat3 activity . Since Stat1 and Stat3 are often expressed simultaneously in the same tumor cells, it has been suggested that one protein dominates over the other in the influence on survival, depending on e.g. the durability of activation of each protein . The Stat1C protein would be expected to function qualitatively as endogenous Stat1 and becomes phosphorylated on Y701 and S727 by interferon-treatment  although it is constitutively present in the nucleus also in the absence of IFN treatment. In the present study we show that Stat1C- expressing cells with constitutive transcriptional activity were sensitized to Fas induced apoptosis by IFN-γ, but that apoptosis induced by the Fas receptor alone was not enhanced in Stat1C- expressing cells as compared to empty vector-transfected cells. This data is consistent with our previous findings [21, 22], but suggests that Stat1 up-regulation is not a sole mediator of the apoptosis sensitizing effect of IFN-γ.
We found that the expression of Stat1C influenced the expression of the apoptosis-related gene Mcl-1 s, while the expression of Bcl-2 and Bcl-xL was not significantly altered in the Stat1C sub-line. Mcl-1 s has previously been characterized as important regulators of survival in MM and interesting therapeutic targets [44, 45]. Harakiri, a pro-apoptotic member of the Bcl-2 family, was also up-regulated in the Stat1C-expressing sub-line. This protein interacts specifically with Bcl-2 and Bcl-XL, counteracting their anti-apoptotic effect . The mRNA expression of the pro-apoptotic Bcl-2 protein Noxa was strongly augmented in U-266-1970-Stat1C. Interestingly, Noxa has previously been shown to be down-regulated in Stat1 (−/−) cells . Its expression has been associated with, amongst others, p53-mediated apoptotic response .
Despite the up-regulation of the pro-apoptotic proteins, introduction of the Stat1C mutant in MM cells did not affect apoptosis in response to any of the 16 drugs selected on the basis of relevance for MM therapy, known Stat1 or Stat3 influence, or novelty. In the HTS of drugs from the LOPAC library and the Spectrum collection we did not observe a general Stat1-dependent difference in apoptosis-sensitivity. However, we could confirm that Stat1C-expressing MM cells were significantly more resistant in response to two similar compounds – gitoxin and gitoxigenin. A major role of Stat1 in promoting apoptosis have previously been challenged by studies showing increased Stat1 expression in cells with acquired resistance to chemotherapeutic drugs and radiation [49, 50]. At present the mechanism(s) for these observations are unknown, but may involve other partners of Stat1 i.e. the ISGF3 (Stat1/Stat2/IRF9 complex) mediated signaling [49, 50].
We conclude that constitutive transcriptional activation of Stat1 alters IL-6 induced activation by Stat3. However, this shift alone is not sufficient to alter sensitivity to apoptosis induced by Fas receptor or sensitivity to therapeutic drugs in MM. This study suggests that also Stat1 independent pathways are operative in IFN mediated apoptosis sensitization and underlines the importance of understanding the details of MM survival pathways in order to exploit them as therapeutic targets.
We thank Pernilla Martinsson and Charlotta Sandberg for excellent technical assistance, and Dr. Sironi and Dr. Ouchi for kindly providing the Stat1C vector.
Supported by grants from the Swedish Cancer Society, the Multiple Myeloma Research Foundation (MMRF), the Swedish Research Council and von Kantzows Stiftelse
- Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K: Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012, 9: 135-143. 10.1038/nrclinonc.2012.15.View ArticlePubMedGoogle Scholar
- Jernberg-Wiklund H, Nilsson K: Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma. Ups J Med Sci. 2012, 117: 166-177. 10.3109/03009734.2012.659293.View ArticlePubMedPubMed CentralGoogle Scholar
- Darnell JE: STATs and gene regulation. Science. 1997, 277: 1630-1635. 10.1126/science.277.5332.1630.View ArticlePubMedGoogle Scholar
- Smithgall TE, Briggs SD, Schreiner S, Lerner EC, Cheng H, Wilson MB: Control of myeloid differentiation and survival by Stats. Oncogene. 2000, 19: 2612-2618. 10.1038/sj.onc.1203477.View ArticlePubMedGoogle Scholar
- Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene. 2000, 19: 2474-2488. 10.1038/sj.onc.1203527.View ArticlePubMedGoogle Scholar
- Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999, 10: 105-115. 10.1016/S1074-7613(00)80011-4.View ArticlePubMedGoogle Scholar
- Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB: Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004, 103: 3175-3184. 10.1182/blood-2003-06-2151.View ArticlePubMedGoogle Scholar
- Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998, 334 (Pt 2): 297-314.View ArticlePubMedPubMed CentralGoogle Scholar
- Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE: Stat3 as an oncogene. Cell. 1999, 98: 295-303. 10.1016/S0092-8674(00)81959-5.View ArticlePubMedGoogle Scholar
- Buettner R, Mora LB, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002, 8: 945-954.PubMedGoogle Scholar
- Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY: Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science. 1996, 272: 719-722. 10.1126/science.272.5262.719.View ArticlePubMedGoogle Scholar
- Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR: Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science. 1997, 278: 1630-1632. 10.1126/science.278.5343.1630.View ArticlePubMedGoogle Scholar
- Lee KY, Anderson E, Madani K, Rosen GD: Loss of STAT1 expression confers resistance to IFN-gamma-induced apoptosis in ME180 cells. FEBS Lett. 1999, 459: 323-326. 10.1016/S0014-5793(99)01283-1.View ArticlePubMedGoogle Scholar
- Stephanou A, Brar BK, Scarabelli TM, Jonassen AK, Yellon DM, Marber MS, Knight RA, Latchman DS: Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem. 2000, 275: 10002-10008. 10.1074/jbc.275.14.10002.View ArticlePubMedGoogle Scholar
- Bauer K, Kretzschmar AK, Cvijic H, Blumert C, Loffler D, Brocke-Heidrich K, Schiene-Fischer C, Fischer G, Sinz A, Clevenger CV, Horn F: Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells. Oncogene. 2009, 28: 2784-2795. 10.1038/onc.2009.142.View ArticlePubMedGoogle Scholar
- Qing Y, Stark GR: Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem. 2004, 279: 41679-41685. 10.1074/jbc.M406413200.View ArticlePubMedGoogle Scholar
- Costa-Pereira AP, Tininini S, Strobl B, Alonzi T, Schlaak JF, Is'harc H, Gesualdo I, Newman SJ, Kerr IM, Poli V: Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc Natl Acad Sci U S A. 2002, 99: 8043-8047. 10.1073/pnas.122236099.View ArticlePubMedPubMed CentralGoogle Scholar
- Stephanou A, Brar BK, Knight RA, Latchman DS: Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ. 2000, 7: 329-330. 10.1038/sj.cdd.4400656.View ArticlePubMedGoogle Scholar
- Page BD, Ball DP, Gunning PT: Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Pat. 2011, 21: 65-83. 10.1517/13543776.2011.539205.View ArticlePubMedGoogle Scholar
- Souissi I, Ladam P, Cognet JA, Le Coquil S, Varin-Blank N, Baran-Marszak F, Metelev V, Fagard R: A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line. Mol Cancer. 2012, 11: 12-10.1186/1476-4598-11-12.View ArticlePubMedPubMed CentralGoogle Scholar
- Spets H, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H: Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood. 1998, 92: 2914-2923.PubMedGoogle Scholar
- Dimberg LY, Dimberg AI, Ivarsson K, Stromberg T, Osterborg A, Nilsson K, Oberg F, Jernberg Wiklund H: Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells. Blood. 2005, 106: 1346-1354. 10.1182/blood-2004-04-1322.View ArticlePubMedGoogle Scholar
- Sironi JJ, Ouchi T: STAT1-induced apoptosis is mediated by caspases 2, 3, and 7. J Biol Chem. 2004, 279: 4066-4074.View ArticlePubMedGoogle Scholar
- Jernberg-Wiklund H, Pettersson M, Carlsson M, Nilsson K: Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia. 1992, 6: 310-318.PubMedGoogle Scholar
- Muller M, Laxton C, Briscoe J, Schindler C, Improta T, Darnell JE, Stark GR, Kerr IM: Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways. Embo J. 1993, 12: 4221-4228.PubMedPubMed CentralGoogle Scholar
- Dimberg A, Nilsson K, Oberg F: Phosphorylation-deficient Stat1 inhibits retinoic acid-induced differentiation and cell cycle arrest in U-937 monoblasts. Blood. 2000, 96: 2870-2878.PubMedGoogle Scholar
- Andrews NC, Faller DV: A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 1991, 19: 2499-10.1093/nar/19.9.2499.View ArticlePubMedPubMed CentralGoogle Scholar
- Lew DJ, Decker T, Strehlow I, Darnell JE: Overlapping elements in the guanylate-binding protein gene promoter mediate transcriptional induction by alpha and gamma interferons. Mol Cell Biol. 1991, 11: 182-191.View ArticlePubMedPubMed CentralGoogle Scholar
- Nilsson E, Lendahl U: Transient expression of a human beta-actin promoter/lacZ gene introduced into mouse embryos correlates with a low degree of methylation. Mol Reprod Dev. 1993, 34: 149-157. 10.1002/mrd.1080340206.View ArticlePubMedGoogle Scholar
- Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002, 30: e57-10.1093/nar/gnf056.View ArticlePubMedPubMed CentralGoogle Scholar
- Eldering E, Spek CA, Aberson HL, Grummels A, Derks IA, de Vos AF, McElgunn CJ, Schouten JP: Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res. 2003, 31: e153-10.1093/nar/gng153.View ArticlePubMedPubMed CentralGoogle Scholar
- O'Brien J, Wilson I, Orton T, Pognan F: Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem. 2000, 267: 5421-5426. 10.1046/j.1432-1327.2000.01606.x.View ArticlePubMedGoogle Scholar
- Pagé B, Pagé M, Noel C: A new fluorometric assay for cytotoxicity measurements in vitro. Int J Oncol. 1993, 3: 473-476.PubMedGoogle Scholar
- Larsson R, Kristensen J, Sandberg C, Nygren P: Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer. 1992, 50: 177-185. 10.1002/ijc.2910500204.View ArticlePubMedGoogle Scholar
- Rickardson L, Fryknas M, Haglund C, Lovborg H, Nygren P, Gustafsson MG, Isaksson A, Larsson R: Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemother Pharmacol. 2006, 58: 749-758. 10.1007/s00280-006-0216-7.View ArticlePubMedGoogle Scholar
- Alas S, Bonavida B: Inhibition of Constitutive STAT3 Activity Sensitizes Resistant Non-Hodgkin's Lymphoma and Multiple Myeloma to Chemotherapeutic Drug-mediated Apoptosis. Clin Cancer Res. 2003, 9: 316-326.PubMedGoogle Scholar
- De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B: JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol. 2000, 109: 823-828. 10.1046/j.1365-2141.2000.02127.x.View ArticlePubMedGoogle Scholar
- Ihle JN: The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001, 13: 211-217. 10.1016/S0955-0674(00)00199-X.View ArticlePubMedGoogle Scholar
- Stephanou A, Latchman DS: Opposing actions of STAT-1 and STAT-3. Growth Factors. 2005, 23: 177-182. 10.1080/08977190500178745.View ArticlePubMedGoogle Scholar
- Hong F, Jaruga B, Kim WH, Radaeva S, El-Assal ON, Tian Z, Nguyen VA, Gao B: Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest. 2002, 110: 1503-1513.View ArticlePubMedPubMed CentralGoogle Scholar
- Scarabelli TM, Townsend PA, Chen-Scarabelli C, Yuan Z, McCauley RB, Di Rezze J, Patel D, Putt J, Allebban Z, Abboud J, et al: Amino acid supplementation differentially modulates STAT1 and STAT3 activation in the myocardium exposed to ischemia/reperfusion injury. Am J Cardiol. 2008, 101: 63E-68E.View ArticlePubMedGoogle Scholar
- Thyrell L, Arulampalam V, Hjortsberg L, Farnebo M, Grander D: Pokrovskaja Tamm K: Interferon alpha induces cell death through interference with interleukin 6 signaling and inhibition of STAT3 activity. Exp Cell Res. 2007, 313: 4015-4024. 10.1016/j.yexcr.2007.08.007.View ArticlePubMedGoogle Scholar
- Bromberg JF: Activation of STAT proteins and growth control. Bioessays. 2001, 23: 161-169. 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0.View ArticlePubMedGoogle Scholar
- Le Gouill S, Podar K, Harousseau JL, Anderson KC: Mcl-1 regulation and its role in multiple myeloma. Cell Cycle. 2004, 3: 1259-1262. 10.4161/cc.3.10.1196.View ArticlePubMedGoogle Scholar
- Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M: Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002, 100: 194-199. 10.1182/blood.V100.1.194.View ArticlePubMedGoogle Scholar
- Inohara N, Ding L, Chen S, Nunez G: harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). Embo J. 1997, 16: 1686-1694. 10.1093/emboj/16.7.1686.View ArticlePubMedPubMed CentralGoogle Scholar
- Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A: STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 2004, 279: 5811-5820.View ArticlePubMedGoogle Scholar
- Shibue T, Takeda K, Oda E, Tanaka H, Murasawa H, Takaoka A, Morishita Y, Akira S, Taniguchi T, Tanaka N: Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 2003, 17: 2233-2238. 10.1101/gad.1103603.View ArticlePubMedPubMed CentralGoogle Scholar
- Fryknas M, Dhar S, Oberg F, Rickardson L, Rydaker M, Goransson H, Gustafsson M, Pettersson U, Nygren P, Larsson R, Isaksson A: STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines. Int J Cancer. 2007, 120: 189-195. 10.1002/ijc.22291.View ArticlePubMedGoogle Scholar
- Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR: STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A. 2004, 101: 1714-1719. 10.1073/pnas.0308102100.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/318/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.